Search research articles
Contact Us
Filters
Showing results (101-110 of 222) with videos related to
Page
of 23
Sort By:
Anticancer Research
|
May 13, 2015
Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer
Thorsten H Ecke, Christian Arndt, Carsten Stephan, et al.
Histology and Histopathology
|
April 9, 2010
Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer
Florian R Fritzsche, Carsten Stephan, Josefine Gerhardt, et al.
ISRN Urology
|
July 26, 2012
External validation of an artificial neural network and two nomograms for prostate cancer detection
Thorsten H Ecke, Steffen Hallmann, Stefan Koch, et al.
Cancer Medicine
|
September 8, 2017
miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy
Thorsten H Ecke, Katja Stier, Sabine Weickmann, et al.
Anticancer Research
|
July 26, 2007
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer
Carsten Stephan, Hellmuth-Alexander Meyer, Eva-Maria Paul, et al.
Urology
|
February 27, 2007
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics
Klaus Jung, Wolfgang Hoesel, Jeanett Reiche, et al.
Plos One
|
October 12, 2012
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients
Hellmuth A Meyer, Tobias Endermann, Carsten Stephan, et al.
The Prostate
|
October 23, 2008
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
Carsten Stephan, Anna-Maria Kahrs, Henning Cammann, et al.
European Urology
|
July 13, 2004
Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16
Monika Jung, Chuanliang Xu, Jan Spethmann, et al.
BJU International
|
March 31, 2015
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years
Martin Boegemann, Carsten Stephan, Henning Cammann, et al.
Page
of 23
Search research articles
Search
Showing results (101-110 of 222) with videos related to
Sort By:
Page
of 23
Anticancer Research
|
May 13, 2015
Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer
Thorsten H Ecke, Christian Arndt, Carsten Stephan, et al.
Histology and Histopathology
|
April 9, 2010
Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer
Florian R Fritzsche, Carsten Stephan, Josefine Gerhardt, et al.
ISRN Urology
|
July 26, 2012
External validation of an artificial neural network and two nomograms for prostate cancer detection
Thorsten H Ecke, Steffen Hallmann, Stefan Koch, et al.
Cancer Medicine
|
September 8, 2017
miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy
Thorsten H Ecke, Katja Stier, Sabine Weickmann, et al.
Anticancer Research
|
July 26, 2007
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer
Carsten Stephan, Hellmuth-Alexander Meyer, Eva-Maria Paul, et al.
Urology
|
February 27, 2007
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics
Klaus Jung, Wolfgang Hoesel, Jeanett Reiche, et al.
Plos One
|
October 12, 2012
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients
Hellmuth A Meyer, Tobias Endermann, Carsten Stephan, et al.
The Prostate
|
October 23, 2008
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
Carsten Stephan, Anna-Maria Kahrs, Henning Cammann, et al.
European Urology
|
July 13, 2004
Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16
Monika Jung, Chuanliang Xu, Jan Spethmann, et al.
BJU International
|
March 31, 2015
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years
Martin Boegemann, Carsten Stephan, Henning Cammann, et al.
Page
of 23